PMV Pharmaceuticals
PMVP | NASDAQ
$1.19
-$0.08 (-6.30%)
At close: Nov 16, 2026, 4:00 PM ET
$1.20
+$0.01 (+0.84%)
After-hours:
Nov 16, 2026, 7:09 PM ET
PMV Pharmaceuticals Company Profile
Company profile explainedCompany Profile
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
Key Executives
| Name | Position |
|---|---|
| David H. Mack | Co-Founder, Chief Executive Officer, President & Director |
| Robert Ticktin | General Counsel, Chief Operating Officer & Company Secretary |
| Arnold J. Levine | Co-Founder, Independent Director & Member of Scientific Advisory Board |
| Binh Vu | Senior Vice President of Drug Discovery & CMC |
| Crystal Zuckerman | Vice President of Human Resources |
| Deepika Jalota | Chief Development Officer |
| Laura De Leon | VP & Head of Clinical Development Operations |
| Marc Fellous | Senior Vice President and Head of Clinical Development & Medical Affairs |
| Michael Carulli | CFO & Principal Financial & Accounting Officer |
| Philip Herman | Chief Commercial Officer |
| Tim Smith | Senior Vice President and Head of Corporate Development & Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 05, 2026 | 4 | Filing |
| Oct 05, 2026 | 3 | Filing |
| Oct 05, 2026 | 8-K | Current Report |
| Sep 15, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 02, 2026 | 8-K | Current Report |
| Sep 02, 2026 | 424B5 | Filing |
| Aug 31, 2026 | 424B3 | Filing |
| Aug 31, 2026 | 424B5 | Filing |
| Aug 31, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 10-Q | Quarterly Report |
PMV Pharmaceuticals
| Country | United States |
| IPO Date | Sep 25, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 54 |
| CEO | David H. Mack |
Contact Details
400 Alexander Park Drive Princeton,
New Jersey 08540 United States
Stock Details
| Ticker Symbol | PMVP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001699382 |
| CUSIP Number | 69353Y103 |
| ISIN Number | US69353Y1038 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove PMVP